A systematic literature review to inform the 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis: management of disease including relapse and complications. (PubMed, EULAR Rheumatol Open) - Oct 11, 2026 - "Of 141 included articles (30 RCTs), low RoB GCA RCTs showed superiority of secukinumab (phase II), mavrilimumab (phase II), and upadacitinib (phase III) vs placebo. Phase II trials of sarilumab and sirukumab were prematurely terminated...TAK RCTs reported similar effectiveness of methotrexate or mycophenolate (some concerns about RoB) and superiority of adalimumab over tocilizumab (high RoB). Phase III PMR RCTs showed tocilizumab and sarilumab superiority (low RoB) over placebo; smaller phase II studies supported rituximab (low RoB) and abatacept (some concerns about RoB). One high RoB RCT showed similar efficacy of tofacitinib and GCs. Multiple phase II and phase III RCTs inform the efficacy and safety of IL-6i, IL-17i, Janus kinase inhibitors, and B cell depletion in GCA and PMR; robust TAK trials remain lacking."
Journal • Review • Fatigue • Giant Cell Arteritis • Immunology • Musculoskeletal Pain • Pain • Polymyalgia Rheumatica • Rheumatology • Vasculitis
|
|
; Alice Bartoletti; Bernhard Hellmich; Chetan Mukhtyar; Durga Prasanna Misra; Elena Nikiphorou; Georgina Ducker; John Losasso; Mrinalini Dey; Paul Studenic; Sara Monti
|